Recombinant Virus Encoding One Or More Heterologous Proteins Or Fragments Thereof Patents (Class 424/199.1)
-
Publication number: 20150056245Abstract: A vaccine is described, comprising an inactivated viral vector having inserted an exogenous nucleotide sequence coding for a disease of concern; and, a pharmaceutically acceptable vehicle, adjuvant or excipient, which provides due protection against the disease of concern by using a viral vector titer similar to that required for an active-virus vaccine based on the same viral vector. Mainly, viral vectors of paramixovirus or adenovirus are described.Type: ApplicationFiled: September 3, 2014Publication date: February 26, 2015Inventors: Bernardo LOZANO-DUBERNARD, David Sarfati-Mizrahi, Jesús Alejandro Suárez-Martínez, Manuel Joaquín Gay-Gutiérrez, Ernesto Soto-Priante
-
Publication number: 20150056235Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: ApplicationFiled: October 6, 2014Publication date: February 26, 2015Inventors: PATTI CYNTHIA CRAWFORD, PAUL J. GIBBS, EDWARD J. DUBOVI, RUBEN OMAR DONIS, JACQUELINE KATZ, ALEXANDER I. KLIMOV, NALLAKANNU P. LAKSHMANAN, MELISSA ANNE LUM, DANIEL GHISLENA EMIEL GOOVAERTS, MARK WILLIAM MELLENCAMP, NANCY J. COX, WILLIAM L. CASTLEMAN
-
Patent number: 8956606Abstract: A malignant tumor cell suppressor protein (a) or (b): (a) a protein comprising an amino acid sequence represented by SEQ ID No. 1; or (b) a protein comprising an amino acid sequence represented by SEQ ID No. 1, wherein one or more amino acid are deleted, substituted or added in the amino acid sequence set forth in SEQ ID No. 1.Type: GrantFiled: June 30, 2006Date of Patent: February 17, 2015Inventors: Toshiwo Andoh, Tetsuo Sugahara, Yoshihide Hayashizaki, Yasushi Okazaki
-
Patent number: 8957029Abstract: The present invention relates to novel peptides capable of binding to action. The peptides are useful in methods for detecting actin in vitro or in living cells.Type: GrantFiled: November 27, 2008Date of Patent: February 17, 2015Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Roland Wedlich-Söldner, Michael Sixt, Julia Riedl, Alvaro Crevenna
-
Publication number: 20150044255Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS virus, RNA molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules. Also provided are isolated polynucleotide molecules further comprising at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope, and vaccines comprising North American PRRS virus, RNA molecules, plasmids and viral vectors comprising such isolated polynucleotide molecules.Type: ApplicationFiled: October 23, 2014Publication date: February 12, 2015Inventors: Jay Gregory CALVERT, Michael G. Sheppard, Siao-Kun W. Welch, Raymond R. R. Rowland, Dal-Young Kim
-
Patent number: 8951535Abstract: The present invention relates to the insertion of a promoter sequence from an MHC class I gene promoter into a lentiviral vector in order to direct the transcription of a transgene, which preferably encodes an immunogenic polypeptide to be expressed in a mammalian cell host, preferably APC (DCs). The invention encompasses these vectors, methods of making the vectors, and methods of using them, including medicinal uses.Type: GrantFiled: April 30, 2013Date of Patent: February 10, 2015Assignee: TheravectysInventors: Cecile Bauche, Emeline Sarry
-
Patent number: 8951534Abstract: The invention relates to therapeutic vaccines for the treatment of neoplasias caused by the human papillomavirus (HPV). In particular, the vaccines of the present invention are formed by chimeric virus-like capsids of birnavirus containing papillomavirus antigens.Type: GrantFiled: November 5, 2010Date of Patent: February 10, 2015Assignee: Chimera Pharma, S.L.UInventors: Thomas Zurcher, Cayetano Von Kobbe, Juan J. Bernal, Ignacio Jiménez Torres, Gloria Calderita Lucas, Margarita Rodriguez Garcia, Ana Garzon Gutierrez, Virginia Gondar Sousa E Silva, Arcadio García De Castro, Irene Pino De La Huerga
-
Patent number: 8945581Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.Type: GrantFiled: October 24, 2011Date of Patent: February 3, 2015Assignee: Transgene S.A.Inventors: Daniel Malarme, Yves Cordier, Claude Sene
-
Patent number: 8945584Abstract: A robust and genetically stable cell culture system for Hepatitis C Virus (HCV) genotype 3a is provided. A genotype 3a/2a (S52/JFH1) recombinant containing the structural genes (Core, E1, E2), p7 and NS2 of strain S52 was constructed and characterized in Huh7.5 cells. S52/JFH1 and J6/JFH viruses passaged in cell culture had comparable growth kinetics and yielded similar peak HCV RNA titers and infectivity titers. Direct genome sequencing of cell culture derived S52/JFH1 viruses identified putative adaptive mutations in Core, E2, p7, NS3, and NS5A; clonal analysis revealed that all genomes analyzed exhibited different combinations of these mutations. Finally, viruses resulting from transfection with RNA transcripts of five S52/JFH1 recombinants containing these combinations of putative adaptive mutations performed as efficiently as J6/JFH viruses in Huh7.5 cells and were all genetically stable after viral passage.Type: GrantFiled: April 11, 2008Date of Patent: February 3, 2015Assignee: Hvidovre HospitalInventors: Judith M. Gottwein, Troels Kasper Høyer Scheel, Jesper Eugen-Olsen, Jens Bukh
-
Patent number: 8945904Abstract: Methods for producing reassortant viruses are provided wherein the transcription and/or translation of the hemagglutinin and/or neuraminidase genes are suppressed.Type: GrantFiled: May 20, 2011Date of Patent: February 3, 2015Assignee: Novartis AGInventors: Heidi Trusheim, Peter Mason, Michael Franti, Bjoern Keiner, Melissa Sackal, Juerg Hunziker, Francois Natt, David Morrissey
-
Publication number: 20150030627Abstract: The present invention relates to multiple novel approaches for the generation of an immune response in an animal, such as a human, using lentivirus-based vector technology. The invention provides for the ability to mimic the efficacy of a live attenuated (LA) vaccine, without exposing the patient to the risk of disease as possible with some LA vaccines. The invention thus provides for systems of complementary conditionally replicating vectors, vectors that produce replication deficient virus like particles, and multi-antigen constructs that target a virus or microbial pathogen. The use of these materials in the practice of the invention permits the generation of robust cellular and humoral responses to the antigens presented thereby.Type: ApplicationFiled: October 8, 2014Publication date: January 29, 2015Applicant: VIRxSYS.CON390Inventors: Xiaobin Lu, Boro Dropulic
-
Publication number: 20150024002Abstract: Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions.Type: ApplicationFiled: August 20, 2014Publication date: January 22, 2015Inventors: Silvia Perri, John Polo, Yasushi Uematsu, Catherine Greer
-
Publication number: 20150024003Abstract: The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, the present in the 5? region nucleotides present in the 5? edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3? region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein E of this vector virus or equivalent functional sequences, and not comprising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein E level and of nonstructural NS1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, having theType: ApplicationFiled: June 13, 2014Publication date: January 22, 2015Inventors: Myrna Cristina Bonaldo, Ricardo Galler
-
Patent number: 8932604Abstract: Recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.Type: GrantFiled: October 19, 2012Date of Patent: January 13, 2015Assignee: Intervet Inc.Inventors: Stephanie Cook, Mohamad Morsey, Gary Petersen, Paulus Jacobus Antonius Sondermeijer
-
Patent number: 8933041Abstract: The present invention is directed to a system for treating individuals at risk of or suffering from breast cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains in a foreign nucleic acid encoding at least one breast cancer antigen.Type: GrantFiled: November 12, 2004Date of Patent: January 13, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dennis L. Panicali, Gail P. Mazzara, Linda R. Gritz, Jeffrey Schlom, Kwong-Yok Tsang, James W. Hodge
-
Patent number: 8926987Abstract: This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.Type: GrantFiled: November 17, 2005Date of Patent: January 6, 2015Assignees: The Government of The United States of America as represented by the Secretary of the Department of Health and Human Services, Istituto Superiore di SanitaInventors: Bo Peng, Rebecca Voltan, Barbara Ensoli, Marjorie Robert-Guroff
-
Patent number: 8927251Abstract: The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells render the HSV particles. particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.Type: GrantFiled: August 30, 2006Date of Patent: January 6, 2015Assignee: The University of ChicagoInventors: Guoying Zhou, Bernard Roizman
-
Publication number: 20150004132Abstract: We have developed DNA and viral vectors that can be used, alone or in combination, as a vaccine against one HIV clade, subtype, or recombinant form of HIV or against multiple HIV clades, subtypes, or recombinant forms. Moreover, the vectors can encode a variety of antigens, which may be obtained from one clade or from two or more different clades, and the antigens selected and/or the manner in which the vectors are formulated (e.g., mixed) can be manipulated to generate a protective immune response against a variety of clades (e.g., the clades to which a patient is most likely to be exposed; with the proportions of the components of the vaccine tailored to the extent of the patient's risk to a particular clade or clades).Type: ApplicationFiled: December 20, 2013Publication date: January 1, 2015Applicants: EMORY UNIVERSITY, Centers for Disease Control and Prevention, The United States of America as Represented by the Department of Health and Human ServicesInventors: Harriet Robinson, James Smith, Ram Amara, Bernard Moss, Salvatore T. Butera, Dennis Ellenberger
-
Patent number: 8920811Abstract: A recombinant adenovirus is applied for treating malignancy of over-expressing proto-oncogene neu/erbB2, wherein an expression cassette, which co-expresses the humanized monoclonal antibody variable region gene of anti proto-oncogene neu/erbB2 and the Mda-7/IL-24 gene, is inserted into E1 deletion region of the recombinant adenovirus. The recombinant adenovirus effectively treats the malignancy of overexpressing proto-oncogene neu/erbB2 without damaging normal cells, such that the recombinant adenovirus is able to be used for the gene therapy of malignancy tumors over-expressing proto-oncogene neu/erbB2.Type: GrantFiled: April 2, 2008Date of Patent: December 30, 2014Inventor: Shangwu Wang
-
Publication number: 20140377306Abstract: The invention is directed to compositions capable of augmenting the immunogenicity of a vaccine. The composition, or adjuvant, is administered to a mammal in need thereof in sequential or concurrent combination with a vaccine antigen. In one preferred aspect, the adjuvant is provided in the form of a recombinant poxvirus vector, such as a vaccinia virus vector, which comprises a nucleic acid sequence encoding IL-15.Type: ApplicationFiled: January 15, 2014Publication date: December 25, 2014Applicant: The United States of America, as represented by the Secretary, Dept. of Health & Human ServicesInventors: Liyanage P. Perera, Thomas A. Waldmann, Sang-Kon Oh, Jay A. Berzofsky
-
Patent number: 8916172Abstract: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.Type: GrantFiled: January 10, 2011Date of Patent: December 23, 2014Assignees: Emory University, National Institute of Allergy and Infectious Diseases (NIAID), The United States of America, as represented by the Department of Health and Human ServicesInventors: Bernard Moss, Linda Wyatt, Patricia Earl, Harriet L. Robinson
-
Publication number: 20140370050Abstract: The present invention includes the Paramyxovirus Parainfluenza Virus 5 (PIV5) as an oncolytic agent for treating various cancers, including, but not limited to breast cancer, lung cancer and melanoma. PIV5 oncolytic agents include both wild type PIV5 and various recombinant PIV5 constructs. Recombinant PIV5 constructs may include PIV5 lacking the conserved C-terminus of the V protein (PIV5VAC), PIV5 with mutations in the N-terminus of the V/P protein (PIV5CPI?), and PIV5 expressing MDA-7/IL-24 (rPIV5-MDA7), rPIV5-V/P-CPI?, rPIV5-CPI+, rPIV-Rev, rPIV5-RL, rPIV5-P-5157A, rPIV5-P-5308A, A1981D, rPIV5-F-5443P, rPIV5-MDA7, rPIV5ASH-CPI?, or rPIV5ASH-Rev. Also included are methods of making and using such oncolytic agents and compositions including such oncolytic agents.Type: ApplicationFiled: January 24, 2013Publication date: December 18, 2014Inventor: Biao He
-
Publication number: 20140363464Abstract: The compositions and methods of the invention described herein provide pre- or post-exposure treatments against filovirus or arenavirus infection by expressing one or more genes (e.g., two or more genes) from filoviruses or arenaviruses in a delivery vehicle (e.g., a recombinant viral vector or a liposome).Type: ApplicationFiled: June 25, 2014Publication date: December 11, 2014Inventor: Thomas William GEISBERT
-
Publication number: 20140356395Abstract: This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in antibiotic resistance as well as methods for vaccinating mammals against polypeptides involved in antibiotic resistance are provided.Type: ApplicationFiled: August 18, 2014Publication date: December 4, 2014Inventor: Michael A. Barry
-
Patent number: 8895027Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.Type: GrantFiled: February 2, 2012Date of Patent: November 25, 2014Assignees: Merial Limited, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Universite Paris-SudInventors: Hervé Poulet, Thierry Heidmann
-
Publication number: 20140341946Abstract: The present invention relates to the rapid induction of a protective immune response against infectious agents using a poxvirus. An immune response can be induced by administering the poxvirus 7 to 2 days prior to infection with the infections agents.Type: ApplicationFiled: July 10, 2014Publication date: November 20, 2014Applicant: BAVARIAN NORDIC A/SInventors: Paul CHAPLIN, Luis MATEO
-
Publication number: 20140341908Abstract: The invention is directed to an improved method to manufacture virus for use in vaccine by culturing infected cells that have been modified to overexpress miR-144. The invention is also directed to manipulating the activity or level of miR-144 in subjects in order to modulate the antiviral and immune response systems.Type: ApplicationFiled: May 20, 2014Publication date: November 20, 2014Applicant: INSTITUTE FOR SYSTEMS BIOLOGYInventors: Carrie M. ROSENBERGER, Alan ADEREM
-
Publication number: 20140335074Abstract: Methods are provided herein for enhancing the effectiveness of medical therapies by administering agents that suppress a biological damage response that is inducible by the medical therapy administered to a subject. In certain embodiments, a method is provided for administering an anti-senescent cell agent that suppresses a biological response comprising cellular senescence that is induced by the medical therapy.Type: ApplicationFiled: December 13, 2012Publication date: November 13, 2014Inventors: Judith Campisi, Marco Demaria
-
Publication number: 20140335047Abstract: The present invention provides a particulate delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload molecule and a payload trapping molecule. The invention further provides methods of making and methods of using the particulate delivery system.Type: ApplicationFiled: November 6, 2013Publication date: November 13, 2014Applicant: UNIVERSITY OF MASSACHUSETTSInventor: Gary R. OSTROFF
-
Publication number: 20140335124Abstract: Recombinant trivalent vaccine against human influenza contains recombinant adenoviral vector with a nucleotide sequence which encodes at least one antigen of influenza virus strain, while non-replicating nanoparticles are used as adenoviral vectors based on genome of human adenovirus of serotype 5, capable of expressing the haemagglutinin of influenza virus which induce human immune response to influenza virus, wherein the vaccine contains composition of three kinds of non-replicating nanoparticles, each of which carries different influenza hemagglutinin genes, further comprises immunostimulant and formulating buffer. In this solution the influenza virus hemagglutinin genes are: H1, H3, HB and any other recommended by the World Health Organization at the time of production. Formulating buffer is added to the composition to achieve a total volume of 0.5 ml and a vaccine dose of 0.5 ml.Type: ApplicationFiled: July 29, 2014Publication date: November 13, 2014Inventors: Rustam R. ATAULLAKHANOV, Maksim M. SHMAROV, Elena S. SEDOVA, Denis U. LOGUNOV, Aleksey V. PICHUGIN, Ravshan I. ATAULLAKHANOV, Rakhim M. KHAITOV
-
Patent number: 8883493Abstract: Compositions and methods useful in transgene expression are provided. Herpes simplex virus type 1 thymidine kinase sequences (“TK sequences”) are used to enhance transgene expression in first generation and high capacity adenoviral vectors. An mCMV promoter-driven ?-galactosidase-expressing cassette is combined with TK sequences through direct fusion of the cDNA's. ?-galactosidase (transgene) expression is enhanced independent of adenoviral vector selection. Methods of enhancing transgene expression employing the inventive adenoviral vectors are provided, along with pharmaceutical preparations comprising the inventive vectors and kits for enhanced transgene expression.Type: GrantFiled: January 30, 2008Date of Patent: November 11, 2014Assignee: Cedars-Sinai Medical CenterInventors: Pedro R. Lowenstein, Maria Castro
-
Patent number: 8883168Abstract: The present invention relates to compositions, methods, and uses involving the modulation of K4 protein activity, especially in the treatment of various diseases and in the enhancement of vaccination regimens. The invention relates to poxviruses having reduced or increased K4 protein activity, as well as methods of making and using these poxviruses. The invention further relates to K4 proteins and inhibitors of K4 protein activity, as well as methods for making and using them.Type: GrantFiled: November 7, 2011Date of Patent: November 11, 2014Assignee: Bavarian Nordic A/SInventors: Jürgen Hausmann, Hubertus Hochrein, Christine Meisinger-Henschel
-
Publication number: 20140328873Abstract: The inventors have successfully developed a recombinant vesicular stomatitis virus which expresses the major capsid protein of human norovirus. Infection of mammalian cells with the recombinant vesicular stomatitis virus resulted in production of high level of human norovirus virus-like particles. Importantly, the inventors further demonstrated that recombinant vesicular stomatitis virus expressing the major capsid protein of human norovirus displayed attenuated virulence in mice and elicited a high level of human norovirus-specific humoral, cellular, and mucosal immune responses in mice model. Therefore, norovirus-immunogenic compositions are herein provided, as are materials and methods useful to make and use the compositions.Type: ApplicationFiled: June 8, 2012Publication date: November 6, 2014Applicant: OHIO STATE INNOVATION FOUNDATIONInventors: Jianrong Li, Yuanmei Ma
-
Publication number: 20140322264Abstract: The invention provides a method for therapeutic treatment of a patient having active tuberculosis (TB), the method comprising: administering to the patient a recombinant adenovirus vector that comprises nucleic acid encoding the Ag85A, Ag85B and TB10.4 antigens of Mycobactium tuberculosis (Mtb). Advantageously, the method can be used to shorten conventional drug therapy for treating active TB.Type: ApplicationFiled: June 10, 2014Publication date: October 30, 2014Inventors: Jerald Charles Sadoff, Anisah Alyahya
-
Publication number: 20140322265Abstract: The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment C for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment C (TTC) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject.Type: ApplicationFiled: November 30, 2012Publication date: October 30, 2014Inventors: Paul Chaplin, Robin Steigerwald
-
Patent number: 8871225Abstract: The present invention provides vectors that contain and express in vivo Leishmania KMP11 or an epitope thereof that elicits an immune response in a dog against Leishmania, compositions comprising said vectors, methods of vaccination against Leishmania, and kits for use with such methods and compositions.Type: GrantFiled: July 20, 2010Date of Patent: October 28, 2014Assignee: Merial LimitedInventor: Laurent Bernard Fischer
-
Patent number: 8871219Abstract: Recombinant vectors which are based on the Modified Ankara Virus (MVA) as preventive and therapeutic vaccines against AIDS. The recombinant viruses contain sequences which are inserted at an MVA insertion site and enable simultaneous expression of antigens, a HIV-1 Env protein consisting of a gp120 protein lacking sequences corresponding to protein gp 41 and a chimeric fusion protein of Gag, Pol and Nef. These viruses are stable and can trigger immune responses against a large variety of antigens. Viruses having a chimeric protein from HIV-1 are suitable for the preparation of vaccines against AIDS.Type: GrantFiled: July 25, 2006Date of Patent: October 28, 2014Assignee: Consejo Superior de Investigaciones CientificasInventors: Jonathan Heeney, Petra Mooij, Carmen Elena Gomez Rodriguez, Jose Luis Najera Garcia, Victoria Jimenez Tentor, Mariano Esteban Rodriguez
-
Patent number: 8871220Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.Type: GrantFiled: April 2, 2010Date of Patent: October 28, 2014Assignee: Merial LimitedInventors: Michel Bublot, Frederic Reynard, François-Xavier Le Gros
-
Patent number: 8871193Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.Type: GrantFiled: June 24, 2013Date of Patent: October 28, 2014Assignees: Catherex, Inc., The General Hospital Corporation, Georgetown UniversityInventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
-
Patent number: 8865182Abstract: The present invention provides replication competent adenoviral vectors capable of expressing antigens from infectious pathogens, such as influenza virus. The adenoviral vectors can be used to vaccinate subjects against the infectious pathogens. The adenoviral vectors comprise heterologous sequences encoding the antigens. The heterologous sequences can be inserted into various locations in the adenoviral vectors, including in or near specific E3 deletions and/or integrated into the adenoviral hexon coding region. The adenoviral vectors can be derived from any adenoviral serotype, particularly an Ad4 or Ad7 serotype.Type: GrantFiled: July 30, 2010Date of Patent: October 21, 2014Assignee: Paxvax, Inc.Inventors: Timothy P. Mayall, Jeff Alexander
-
Patent number: 8852602Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.Type: GrantFiled: October 18, 2011Date of Patent: October 7, 2014Inventors: David M. Koelle, Lawrence Corey
-
Patent number: 8852607Abstract: Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination with one or more dihydric or polyhydric alcohols, and, optionally, a detergent, such as a sorbitan ester. Also described are methods of using the compositions.Type: GrantFiled: May 4, 2012Date of Patent: October 7, 2014Assignee: Genzyme CorporationInventors: Hema S. Sista, Yero J. Espinoza
-
Publication number: 20140294893Abstract: The present invention relates to the field of veterinary vaccines, in particular to that of vector vaccines for poultry based on recombinant nonpathogenic Marek's disease virus (npMDV). The recombinant npMDV of the invention expresses stably and effectively two heterologous genes each originating from a different micro-organism: the fusion protein gene from Newcastle disease virus, and the viral protein 2 gene from infectious bursal disease virus. A vaccine based on this recombinant npMDV can be used to induce in poultry a protective immune response not only against Marek's disease, but also against Newcastle disease and Infectious bursal disease. The invention also relates to methods and uses involving the recombinant npMDV, expression cassette, infected host cells, and vaccines.Type: ApplicationFiled: October 19, 2012Publication date: October 2, 2014Inventors: Paulus Jacobus Antonius Sondermeijer, Iwan Verstegen
-
Publication number: 20140294892Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.Type: ApplicationFiled: June 16, 2014Publication date: October 2, 2014Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
-
Publication number: 20140294890Abstract: Recombinant adenovirus vaccines comprising recombinant adenoviruses whose hexon, fiber or protein IX capsid proteins are engineered to include exogenous peptide segments, e.g. vaccines for human papillomavirus (HPV) and malaria.Type: ApplicationFiled: July 19, 2013Publication date: October 2, 2014Applicant: The Johns Hopkins UniversityInventors: Gary W. Ketner, Richard B.S. Roden, Fidel P. Zavala
-
Publication number: 20140294891Abstract: Therapeutic methods and vaccinia virus therefor are provided. The viruses are designed so that they accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms.Type: ApplicationFiled: June 11, 2014Publication date: October 2, 2014Inventors: Aladar A. Szalay, Tatyana Timiryasova, Yong A. Yu, Qian Zhang
-
Publication number: 20140271677Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, James Allison, Jedd D. Wolchok
-
Publication number: 20140271708Abstract: The present invention relates to compositions comprising replication defective chimeric flavivirus anti-rabies vaccines, methods of producing the vaccines, and the administration of such vaccines to companion animals, including dogs. The invention further relates to methods for providing long-term protective immunity against rabies in companion animals, including dogs and cats.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: MERIAL LIMITEDInventor: Frederic David
-
Publication number: 20140248308Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.Type: ApplicationFiled: October 5, 2012Publication date: September 4, 2014Inventors: Duncan McVey, Douglas E. Brough, Jason G.D. Gall
-
Publication number: 20140248306Abstract: The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors can be either integrative or non-integrative vectors. The invention encompasses prophylactic, therapeutic, symptomatic, and curative treatments of animals, including humans, as well as gene therapy and vaccination in vivo.Type: ApplicationFiled: March 5, 2014Publication date: September 4, 2014Applicants: INSTITUT PASTEUR, THERAVECTYS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Pierre CHARNEAU, Anne-Sophie BEIGNON, Frederic Philippe COUTANT, Karine COURBEYRETTE